NxStage Medical, Inc. (NXTM) Given Consensus Rating of “Hold” by Brokerages
NxStage Medical, Inc. (NASDAQ:NXTM) has been assigned an average rating of “Hold” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and nine have issued a hold rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $30.00.
Several equities analysts recently weighed in on NXTM shares. Zacks Investment Research downgraded NxStage Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Canaccord Genuity reiterated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a research report on Tuesday, October 17th. Finally, Northland Securities reiterated a “hold” rating and set a $30.00 target price on shares of NxStage Medical in a research report on Wednesday, November 8th.
NxStage Medical (NASDAQ:NXTM) traded up $0.31 during midday trading on Friday, reaching $25.07. The company had a trading volume of 1,087,208 shares, compared to its average volume of 339,014. NxStage Medical has a 1 year low of $20.45 and a 1 year high of $30.80. The stock has a market capitalization of $1,639.91, a P/E ratio of -358.14 and a beta of -0.08.
Large investors have recently made changes to their positions in the business. Prudential Financial Inc. acquired a new stake in NxStage Medical during the third quarter worth about $202,000. Amalgamated Bank increased its stake in NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after acquiring an additional 553 shares during the last quarter. Athos Capital Ltd acquired a new stake in NxStage Medical during the third quarter worth about $557,000. Suntrust Banks Inc. increased its stake in NxStage Medical by 2.3% during the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock worth $237,000 after acquiring an additional 209 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in NxStage Medical during the second quarter worth about $269,000. Institutional investors own 85.58% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/nxstage-medical-inc-nxtm-given-consensus-rating-of-hold-by-brokerages/1828268.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.